3CHALON S A,GRANIER L A,VANDENHENDE F R,et al.Duloxetine increases serotonin and norepinephrine availability in healthy subjects:a double-blind,controlled study[J].Neuropsychopharmacology,2003,28(9):1685-1693.
4CACCIA S.Metabolism of the newest antidepressants:comparisons with related predecessors[J].Ther Drugs,2004,7(2):143-150.
5SHARMA A,GOLDBERG M J,CERIMELE B J.Phamacokinetics and safety of duloxetine,a dual-serotonin and norepinephrine reuptake inhibitor[J].Clin Pharmacol,2000,40(2):161-167.
6DETKE M J,LU Y,GOLDSTEIN D J,et al.Duloxetine,60 mg once daily,for major depressive disorder:a randomized double-blind placebocontrolled trial[J].Clin Psychiatry,2002,63(4):308-315.
7GOLDSTEIN D J,MALLINCKRODT C H,FERGUSON M B.Duloxetine in the long-term treatment of major depressive disorder.Raskin[J].Clin Psychiatry,2003,64(10):1237-1244.
8VIKTRUP L,PANGALLO B A,DETKE M J,et al.Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence.[J].Lin Psychiatry,2004,6(2):65-73.
9SKINNER M H,KLUAN H Y,PAN A,et al.Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers[J].Clin Pharmacol Ther,2003,73(3):170-177.
